NSAID Use For Alzheimer’s Prevention Future Research Suggested In JAMA
This article was originally published in The Tan Sheet
Executive Summary
Future research on non-steroidal anti-inflammatory drugs and Alzheimer's disease may need to focus on prevention rather than treatment, an editorial in the June 4 Journal of the American Medical Association suggests
You may also be interested in...
Anti-inflammatories
Active recruitment for Alzheimer's Disease Anti-inflammatory Prevention Trial began Jan. 30; target enrollment is 2,625 adults over age 70. The National Institute on Aging-sponsored trial will compare effects of Bayer's Aleve (naproxen sodium), Searle/Pfizer's Rx COX-2 Celebrex (celecoxib) and placebo on age-related memory loss among healthy participants with a family history of dementia or Alzheimer's. The four-center, seven-year trial headed by John Breitner, MD, Johns Hopkins School of Hygiene & Public Health, resembles another NIA trial investigating effects of Merck's Vioxx and Aleve on cognitive decline in Alzheimer's patients; the latter trial hopes to produce results by 2002 (1"The Tan Sheet" Feb. 21, 2000, p. 13)
NSAID use lowers relative risk of developing Alzheimer's -- NIA prospective study.
NSAID USE LOWERS RELATIVE RISK OF ALZHEIMER's DISEASE among participants of the National Institute on Aging's Baltimore Longitudinal Study of Aging. The study followed 1,686 participants from 1980 to 1995, comparing risks of developing Alzheimer's disease in users of aspirin or other nonsteroidal anti-inflammatory drugs and users of acetaminophen. A report on the study by Walter Stewart, PhD, Johns Hopkins, et al., is published in the March issue of Neurology.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC